Latest News - Clinical Trials

Monday, December 03, 2018

Clobazam Oral Film Provides a Highly Consistent and Easy-to-Give Dose

A new oral-film formulation of clobazam (Sympazan; Aquestive, Warren, NJ) was recently approved by the Food and Drug Administration (FDA) for adjunctive treatment of people with seizures associated wi…

Read the full story

Sunday, December 02, 2018

Long-Term Seizure Reduction With Responsive Neurostimulation

At the American Epilepsy Society Annual Meeting in New Orleans, LA, results were announced from a 9-year prospective study of treatment with responsive neurostimulation (RNS) (RNS System; NeuroPace, M…

Read the full story

Sunday, December 02, 2018

Safety and Equivalency of Buccal Film Formulation of Diazepam in Peri-ictal and Interictal Periods

In results presented at the American Epilepsy Society (AES) Annual Meeting in New Orleans, LA, bioavailability and safe administration of a buccal film formulation of 12.5 mg diazepam (Aquestive, Warr…

Read the full story

Saturday, December 01, 2018

Cannabidiol Has Long-Term Dose-Dependent Efficacy That Does Not Impact Behavior or Depend on Type of SCNA1 Mutation

A pharmaceutical grade, highly purified cannabidiol (CBD) (Epidiolex; Greenwich Biosciences, CA) was recently approved and made available for treatment of patients with seizures related to Lennox-Gast…

Read the full story

Saturday, December 01, 2018

First Report from North American SUDEP Registry Presented

At the annual meeting of the American Epilepsy Society, data were, for the first time, reported from the North American SUDEP Registry (NASR), a retrospective repository of medical data from persons w…

Read the full story

Monday, November 26, 2018

Eye Exam May Lead to Early Diagnosis of Creutzfeldt-Jakob Disease

A National Institutes of Health (NIH) study found that the eye may be a source for early diagnosis of Creutzfeldt-Jakob disease (CJD). The findings also raise the possibility of the disease being spre…

Read the full story

Thursday, August 23, 2018

FDA Grants Marketing Approval for Brainsway Ltd’s Brain Stimulation Device for OCD

The US Food and Drug Administration (FDA)granted marketing approval of August 17 for Brainsway Ltd’s deep intracranial magnetic stimulation (dTMS) system for the treatment of obsessive-compulsiv…

Read the full story

Thursday, August 02, 2018

Heading the Ball in Soccer May Affect Women's and Men's Brains Differently

In a new study from researchers at the Albert Einstein College of Medicine (Radiology. 2018;July 31), imaging findings suggest that heading the ball in soccer may affect women's brains differently…

Read the full story

Wednesday, June 20, 2018

Impulse Control Disorders More Common in People Who Take Dopamine Agonists

A French study which followed 411 people for an average of three years who had been diagnosed with Parkinson’s disease (PD) within 5 years, has reported an increase in impulse control disorders …

Read the full story

Wednesday, June 13, 2018

Risk for Parkinson’s Disease May Be Linked to an Earlier Diagnosis of Diabetes

A study from England published online in Neurology on June 13 suggests that people with type 2 diabetes may have an increased risk of developing Parkinson’s disease (PD) later in …

Read the full story

Friday, June 01, 2018

BrainStorm to Host Phone Discussion of Right to Try Legislation and Stem Cell Therapy June 7th

Brainstorm Cell Therapeutics Inc (New York, NY) will host a phone call on June 7th at 8:15 AM EDT to provide interested parties an opportunity to engage with the company regarding new “right-to-…

Read the full story

Tuesday, April 24, 2018

First Results in Humans for Antisense Oligonucleotide Treatment of Patients with Huntington’s Disease

At the American Academy of Neurology meeting in Los Angeles, researchers Sarah Tabrizi, Blair Leavitt, Holly Kordasiewicz, and others presented their results using antisense oligonucleotides (ASO) (IO…

Read the full story

Thursday, March 22, 2018

Phase 3 Clinical Trial Shows Siponimod Significantly Improved Outcomes in Patients With Secondary Progressive Multiple Sclerosis

Results from the phase 3 clinical trial, EXPAND, studying oral, once-daily siponimod (Novartis; East Hanover, NJ) for treatment of secondary progressive multiple sclerosis (SPMS) were published today …

Read the full story

Tuesday, March 20, 2018

Global Alzheimer's Platform Foundation Partners with Lyft to Provide Free Transportation to Research Sites for Clinical Trial Participants

In partnership with Lyft (San Francisco, CA), the Global Alzheimer's Platform Foundation (GAP) (Washington, DC) is beginning a pilot program to provide free transportation to and from research sit…

Read the full story

Wednesday, March 14, 2018

Results From Cannabidiol Dose-Ranging Safety Trial for Treating Patients With Dravet Syndrome

Previous randomized controlled trials have suggested that orally administered cannabidiol (CBD) is effective as an add-on to existing antiepileptic drugs (AEDs) for the treatment of convulsive seizure…

Read the full story
Load More